Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Inclusion Criteria: * Written informed consent can be provided, and understanding and compliance with research requirements and evaluation schedules are required. * On the date of signing the informed consent form, the age range is between 18 and 65 years old (or the legal age specified by local laws). * Pathological diagnosis is non keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated, i.e. WHO classification II or III). * Clinical staging is anyTN2-3M0 or T4N1M0 (AJCC8th/UICC staging). * ECOG score is 0-1 points. * Hemoglobin (HGB) ≥ 90g/L, white blood cell (WBC) ≥ 4.0 × 109/L, platelet (PLT) ≥ 100 × 109/L. * Liver function: ALT and AST\<2.5 times the upper limit of normal (ULN), total bilirubin\<2.0 × UL, serum albumin ≥ 28g/L. * Renal function: Serum creatinine\<1.5 × ULN or creatinine clearance rate (CrCl) calculated value ≥ 60mL/min (Cockcroft Gault formula). * Thyroid stimulating hormone (TSH) ≤ 1 × ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously. If FT3 and FT4 levels are normal, they can be included in the group). * The international normalized ratio (INR) and activated partial thromboplastin time (APTT) are ≤ 1.5 × ULN (unless the subject is receiving anticoagulant treatment and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant treatment at the time of screening). Exclusion Criteria: * Nasopharyngeal cancer patients with recurrence and distant metastasis. * Pathology shows k…